Affymax Announces Second Quarter 2012 Financial Results Teleconference and Webcast

Affymax Announces Second Quarter 2012 Financial Results Teleconference and Webcast

Affymax, Inc.Alexandra Santos, 650-812-8961Associate Director, Corporate Communications

Affymax, Inc. (Nasdaq: AFFY) today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its second quarter 2012 financial results on Wednesday, August 8, 2012, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Financial results for the quarter ended June 30, 2012 will be released after market close on August 8, 2012.

Interested parties can listen to the live teleconference by dialing (866) 393-1565 from the U.S. or +1(973) 409-9608 for international callers. Individuals may access the live audio webcast by visiting: . A replay of the webcast will be available on the Company's website for 30 days following the live event.

Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax's mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses.

The company's first marketed product, OMONTYS (peginesatide) Injection, was approved by the U.S. Food and Drug Administration (FDA) in March 2012. For additional information, please visit .

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.